Myrobalan Therapeutics

Myrobalan is proud to be a local sponsor of the Walk to Defeat ALS in Boston on Oct 20th. This signature event is focused on supporting and advocating for patients and families living with ALS, a prominent and debilitating neurodegenerative disease with no cure. Myrobalan is deeply committed to discovering first and best-in-class small molecule treatments for neurodegenerative diseases such as ALS. Help us make strides toward treatments and cures by donating to the ALS Association.?

We are excited to present our poster on our oral, CNS-penetrant CSF1R inhibitor at the Society for Neuroscience 2024 in Chicago! We look forward to making strides toward therapies for patients suffering from neuroinflammatory diseases. ? ?? Title: Targeting Chronically Active Microglia: CSF1R Inhibition for Treating Multiple Sclerosis ?? Date: Sunday, October 6, 2024 ? Time: 1:00- 5:00 p.m. Central Time ?? Session: Multiple Sclerosis, Leukodystrophies, and Oligodendrocyte Myelination Poster#: PSTR105.18 ? #SfN24 #Neuroscience #Innovation #Neuroinflammation

We are thrilled to announce the creation of a new role at Myrobalan: Interim Chief Medical Officer (CMO). This position reflects our growing commitment to advancing our pipeline and bringing life-changing therapies to patients in need. With our lead program moving into the clinic next year, having strong medical and clinical leadership is more crucial than ever. We’re looking forward to welcoming a passionate and experienced leader who will help guide us through this pivotal phase and beyond. Stay tuned for more updates as we continue to expand our team and capabilities! #Hiring

ICYMI, we are presenting data on our GPR17 program at ECTRIMS today! https://lnkd.in/ev4djYms

We are pleased to announce our upcoming poster presentation at ECTRIMS 2024 in Copenhagen! Our team will be showcasing a poster on our GPR17 antagonist program, a novel remyelination target. ?? Date: Wednesday, 18 September 2024 ? Time: 16:15 – 18:15 CEST ?? Location: Poster Session 1, Poster # P171 Join us to learn more about our research aimed at developing innovative therapies for demyelinating diseases. #ECTRIMS2024 #Remyelination #DemyelinatingDiseases #Neuroscience #GPR17 #Innovation

We are thrilled to welcome Grant Bogle to the Board of Directors at Myrobalan Therapeutics! ? Grant brings a wealth of experience, having served as CEO of Epizyme, Inc. from 2021-2022 and as a Board Member from 2019-2022 until its acquisition by Ipsen in 2022. Prior to that, he was the SVP and COO of TESARO, which was acquired by GSK for $5.1B in 2018. He has also held senior executive roles at several other renowned pharmaceutical and biotech companies, including Millennium, ViaCord, Roche, Knoll, and McKesson Specialty Health/U.S. Oncology. ? This announcement comes just a month after Myrobalan Therapeutics raised an additional $9 million from three new investors in a subsequent closing of its Series A round, bringing total Series A funding to $33 million. ? We are incredibly excited to have Grant join us as we continue our journey as a leading CNS biotech company. Welcome to the Board, Grant! See the full press release here: https://lnkd.in/e-P56Gqd https://lnkd.in/epiw4ESZ

Yesterday, the Myrobalan Therapeutics Medford team traded our laptops for life vests, paddles, and kayaks. We had an amazing time heading down the Mystic River, where we saw turtles, herons, and other local wildlife. We hope they weren't too disturbed by our kayak dodgeball game…?? ? Here’s to many more adventures together and to the wonderful team that makes Myrobalan a great place to work!

Congratulation and Welcome to our Q2 New Hires! We are thrilled to have you join the team and know you will make an impact addressing the unmet need posed by neurodegenerative and demyelinating disorders.? ? Richard Gallegos, Associate Director, DMPK Bowie T., Sr. Accountant? Simon Mazza-Lunn, Associate Director, Program Management?

We are thrilled to announce that Myrobalan Therapeutics Co-Founder, Professor Guoping Feng of Massachusetts Institute of Technology and the Broad Institute of MIT and Harvard, has been inducted into the National Academy of Sciences (NAS)! This prestigious honor recognizes Professor Feng's exceptional contributions to the field of neuroscience. His research has also been foundational to the inception of our own company. Professor Feng is also a member of the National Academy of Medicine (NAM), further highlighting his profound impact on the scientific and medical community. Join us in congratulating Professor Feng on this well-deserved recognition!

ICYMI - Brad Loncar from BiotechTV interviewed Myro at MassBio's #AlignSummit2024. See the quick take from our CEO, Dr. Jing Wang.